Form 4: Insmed COO Roger Adsett Executes Stock Sale
Insider Transaction Report
Insmed Incorporated Chief Operating Officer Roger Adsett sold 5,837 shares of common stock to cover tax obligations.
Summary
- Chief Operating Officer Roger Adsett sold 5,837 shares of Insmed Inc (INSM) common stock.
- The transaction occurred on May 13, 2026, at a price of $116.18 per share.
- The sale was conducted to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
- Following the transaction, the reporting person retains beneficial ownership of 100,973 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and related to tax obligations rather than a strategic divestment.
Positives
- The sale was non-discretionary, specifically executed to cover tax liabilities associated with RSU vesting, rather than a signal of lack of confidence in the company.
Negatives
- Reduction in the direct equity stake held by a key member of the executive leadership team.
Risks
- None identified; this is a routine administrative transaction related to compensation vesting.
Future Outlook
Not applicable; this is a retrospective disclosure of an insider transaction.
Management Comments
- The filing notes that the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.
Industry Context
StockSavvy.ai notes that routine insider selling for tax coverage upon RSU vesting is a standard practice in the biotechnology sector and generally does not reflect management's outlook on company performance.
Comparison to Industry Standards
- The transaction aligns with standard executive compensation practices where equity awards are partially liquidated to cover mandatory tax withholdings.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned for tax purposes.
Next Steps
- None
Key Dates
| Date | Description |
|---|---|
| 05/13/2026 | Date of the stock sale transaction. |
| 05/15/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Insmed, INSM, Insider Trading, Form 4, Biotech, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.